A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Interstitial lung diseases; Myositis
- Focus Proof of concept; Therapeutic Use
- Acronyms ATtackMy-ILD
- 07 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 30 Aug 2017.
- 21 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 1 Aug 2017.
- 14 Jul 2017 New trial record